AVDL News and Press, Avadel Pharmaceuticals plc From 03/31/23

2023-03-31 21:25:09 ET Avadel Pharmaceuticals plc (AVDL) Q4 2022 Earnings Conference Call March 30, 2023 8:30 AM ET Company Participants Austin Murtagh – Stern Investor Relations Greg Divis – Chief Executive Officer Jennifer Gudeman – Senior ...

2023-03-30 07:44:45 ET Avadel Pharmaceuticals press release ( NASDAQ: AVDL ): Q4 GAAP EPS of -$0.44 misses by $0.17 . Cash, cash equivalents and marketable securities were $96.5 million as of December 31, 2022.The Company extended the maturity of $96.2 million of its c...

• LUMRYZ™ NDA amendment filed March 1 requesting FDA final approval • Received FDA authorization to import LUMRYZ in advance of final approval decision; shortens timeline between potential approval and product availability • Secured $200 milli...

2023-03-30 05:16:26 ET Avadel Pharmaceuticals ( NASDAQ: AVDL ) priced its underwritten public offering of 10M shares, nominal value $0.01/share in the form of ADS and 4.7M Series B Non-Voting Convertible Preferred Shares, convertible into ordinary shares on a one-for-one ...

DUBLIN, Ireland, March 29, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 30, 2023, to pro...

DUBLIN, Ireland, March 29, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (“Avadel”) (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today the pricing of an underwritten public offering of 10,000,001 of its ordinary sh...

2023-03-29 17:08:55 ET Avadel Pharmaceuticals ( NASDAQ: AVDL ) on Wednesday said it had entered into a royalty agreement to support the potential commercialization of its sleep disorder drug Lumryz. The company said it had entered into a deal with RTW Investments and certain o...

DUBLIN, Ireland, March 29, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (“Avadel”) (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it is commencing an underwritten public offering of its ordinary shares, n...

– In parallel, extended maturity on $96.2 million of convertible notes to April 1, 2027 – Strategic financings strengthen the company’s balance sheet in advance of potential commercialization of LUMRYZ DUBLIN, Ireland, March 29, 2023 (GLOBE NEWSWIRE) -- Avadel Pharm...

2023-03-22 08:21:40 ET 89bio ( ETNB ) +50% on topline data for NASH candidate. GameStop ( GME ) +48% on Q4 earnings. Telesis Bio ( TBIO ) +17% on Q4 earnings. Pyxis Oncology ( PYXS ) +11% on Q4 earnings. Ollie's Bargain O...